AVR

Anteris Technologies Global Corp. Common Stock

3.80 USD
+0.10
2.70%
Updated Aug 26, 1:54 PM EDT
1 day
2.70%
5 days
4.11%
1 month
13.43%
3 months
-20.83%
6 months
-50.07%
Year to date
-31.53%
1 year
-32.14%
5 years
-32.14%
10 years
-32.14%
 

About: Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.

0
Funds holding %
of 7,431 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

7% more funds holding

Funds holding: 54 [Q1] → 58 (+4) [Q2]

1% more capital invested

Capital invested by funds: $79.5M [Q1] → $80.2M (+$741K) [Q2]

13.31% less ownership

Funds ownership: 60.69% [Q1] → 47.38% (-13.31%) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for AVR.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Anteris Announces Results for the Second Quarter of 2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights 130 patients implanted with the DurAVR® THV since the start of clinical development; 49 patients treated year-to-date; 21 in the quarter World first “double DurAVR®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions Advanced preparatory work for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial") including qualifying additional clinical sites (79 sites now qualified) Held global investigator meeting for the PARADIGM Trial in June, with Dr. Michael J.
Anteris Announces Results for the Second Quarter of 2025
Neutral
GlobeNewsWire
2 months ago
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr.
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Charts implemented using Lightweight Charts™